针对胰腺癌响应性纳米药物平台的策略,针对瘤低毒环境
Kyung Seo Joo1,2, Sun Jin Sym3, Kwang-Min Kim1,2,4
1Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, 21999, South Korea.
International journal of nanomedicine
|November 13, 2025
概括
针对低氧瘤微环境 (TME) 的智能纳米载体对胰腺癌有希望. 这些对缺氧反应的纳米粒子 (NP) 提高了药物输送和疗效,为癌症治疗提供了新的途径.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 胰腺管道腺癌 (PDAC) 是一种致命的癌症,其特点是缺氧和脱质瘤微环境 (TME).
- 这种TME阻碍了药物输送,并促进了对常规疗法的耐药性,包括化疗,放射治疗和免疫治疗.
- 缺氧虽然是一种障碍,但也代表了先进的纳米载体系统可以利用的漏洞.
研究的目的:
- 审查最近对低氧反应性纳米粒子 (NP) 平台的进展,以克服PDAC中的治疗障碍.
- 突出设计NP的策略,利用瘤缺氧进行向药物递送和提高疗效.
- 讨论人工智能 (AI) 在优化胰腺癌治疗的NP设计中的整合.
主要方法:
- 具有缺氧触发的药物释放机制的NP的发展 (生物修复性可切割的链接剂,缺氧激活的前期药物).
- 用瘤向配体 (吸收体,抗体) 对NP进行表面功能化,以提高特异性.
- 多刺激响应NP的设计,结合pH,酶或外源触发器以及缺氧响应.
- 整合人工智能加速NP设计,识别结构功能关系,以及瘤积累的in silico预测.
主要成果:
- 在PDAC模型中的临床前研究表明,这些NP具有显著的治疗潜力.
- 与对照组相比,观察到超过两倍的瘤生长抑制.
- 获得了60%的内死症增加,验证了开发的纳米药物的体内疗效.
结论:
- 对低氧反应的NP提供了一种有希望的策略,以增强药物输送和克服胰腺癌的耐药性.
- 有针对性的药物释放和多刺激响应性改善治疗结果,减少非目标效应.
- 人工智能驱动的NP设计加速了个性化纳米药物的开发,以更有效地治疗胰腺癌.
关键词:
我们的PDAC是PDAC.人工智能辅助的纳米医学低氧激活的前药物是低氧激活的前药物.低氧反应的纳米粒子.胰腺管道腺癌瘤个性化癌症疗法 个性化癌症疗法药物输送是响应刺激的药物.没有了,没有了,没有了瘤微环境是一个微环境.瘤向性带是瘤向性的带.更多相关视频
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
3.5K
07:54Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
8.6K
相关概念视频
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K